



12<sup>th</sup> September 2011

Company's Announcement Office  
ASX Limited  
Exchange Centre  
20 Bridge Street  
Sydney NSW 2000

### **ASX ANNOUNCEMENT / MEDIA RELEASE**

#### **Patent update for Mix&Go™**

- **European Patent for "Generation of Surface Coating Diversity" granted**

Anteo Diagnostics Limited (ASX:ADO) is pleased to announce that the European Patent Office has granted the "Generation of Surface Coating Diversity" patent that was announced as "intended to grant" in March 2011.

The Generation of Surface Diversity patent covers the intellectual property that led to the discovery of the Mix&Go™ technology. Having this patent granted ensures that the process that was used to bind antibodies to more than 8,000 different types of surfaces cannot be copied in the European market. Additional screening exercises that could be initiated to identify new "glues" for a broad range of other industries and sectors will also be covered under this patent.

- **Australian Patent Office accepts application for "Use of Metal Complexes" patent for Mix&Go™**

The Australian Patent Office has issued confirmation that it has accepted Anteo's application for the "Use of Metal Complexes" Australian patent. Whilst this patent application has been accepted, in line with industry standards, it is expected the patent will be granted to Anteo, typically within 6 months.

There are many commercially important reasons to bind biological molecules onto synthetic materials such as plastics, for instance, creating pathology tests for various diseases. These molecules are often fragile and do not react well when exposed to non-biological conditions. The "Use of Metal Complexes" patent covers the use of Mix&Go™ to facilitate this binding process. Anteo has demonstrated that the benefits of Mix&Go™ over existing methods are both numerous and significant from technical and commercial perspectives. Further, the Mix&Go™ concept, a "glue", has broad applications in non-biological settings as well as the biological settings that are currently being pursued.

***Anteo Diagnostics Limited*** ABN 75 070 028 625

Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113

**Phone** 07 3219 0085 **Fax** 07 3219 0553 **Email** [contact@anteodx.com](mailto:contact@anteodx.com) **Web** [www.anteodx.com](http://www.anteodx.com)

For personal use only



- **Further strengthens ADO's IP protection of Mix&Go™**

The acceptance of this patent is important to Anteo as it protects the Intellectual Property (IP) of the Mix&Go™ technology, as well as the methods for generating alternative versions of Mix&Go™. The current version of Mix&Go™ has been shown to be effective in immobilizing antibodies to magnetic beads in the development of pathology tests. A different version may be more effective in developing more efficient systems from water purification to purification of new protein drugs. Additional patents have been filed to extend the protection offered over Mix&Go™.

Anteo's Chief Executive Officer, Dr Geoff Cumming commented: "Protecting the Mix&Go™ technology is of critical importance for Anteo. The grant of the European patent and the acceptance of the Australian patent application are further steps in building greater value into this game-changing technology and protecting our IP. As we advance negotiations for new licensing agreements for Mix&Go™, protecting its value in this large and strategically important market is paramount.

**For further information please contact:**

**Dr Geoff Cumming, CEO, Anteo Diagnostics Limited**  
Tel: +612 8823 3110

***Anteo Diagnostics Limited*** ABN 75 070 028 625

Unit 4, 26 Brandl Street, Eight Mile Plains Qld 4113

**Phone** 07 3219 0085 **Fax** 07 3219 0553 **Email** [contact@anteodx.com](mailto:contact@anteodx.com) **Web** [www.anteodx.com](http://www.anteodx.com)